Wandercraft SAS

Founded in 2012 in Paris, France, Wandercraft SAS focuses on creating assistive technologies, particularly the Personal Exoskeleton. In June 2025, Wandercraft SAS raised an undisclosed amount in series D funding from new investors Renault Group, AG2R La Mondiale Gestion d’Act, and Teampact Ventures. Returning investors European Investment Bank, LBO France, Mutuelles Impact, Cemag Invest, Bpifrance Investissement, Martagon Family Office, Quadrant Management, and other unspecified investors also participated in the round. The round was part of a larger EUR 64.

3 million in series D and debt round. The company is co-founded by Alexandre Boulanger, Jean-Louis Constanza, and Nicolas Simon, with Matthieu Masselin as the CEO. Wandercraft has completed a total of 10 deals since its inception, establishing a notable presence in the healthcare technology sector. Wandercraft specializes in developing the Personal Exoskeleton, an advanced assistive device that employs hybrid robotics technology.

Unveiled on December 13th, 2023, this innovative product targets individuals with walking disabilities, facilitating enhanced mobility both in domestic and public environments. The Personal Exoskeleton aims to empower users by promoting independence and addressing health concerns associated with sedentary lifestyles. The company serves a diverse client base, including rehabilitation centers, hospitals, and private users across multiple geographical markets, including Europe and North America. The focus on enabling seamless movement for those with mobility challenges underscores Wandercraft's commitment to improving the quality of life for its end users.

Wandercraft generated revenue of EUR 2,108,973 in 2022, reflecting its ongoing sales activities. The revenue model is structured around direct sales of the Personal Exoskeleton to healthcare and rehabilitation sectors, which include both direct-to-consumer and business-to-business sales. This allows clients to acquire the exoskeleton through one-time purchases or leasing agreements, fostering long-term relationships with healthcare facilities aiming to enhance patient care through innovative assistive technologies. Notably, the company recorded an EBITDA of EUR -9,091,282.

2 for the same year. In June 2025, Wandercraft SAS raised an undisclosed amount in series D funding from new investors Renault Group, AG2R La Mondiale Gestion d’Act, and Teampact Ventures. Returning investors European Investment Bank, LBO France, Mutuelles Impact, Cemag Invest, Bpifrance Investissement, Martagon Family Office, Quadrant Management, and other unspecified investors also participated in the round. The round was part of a larger EUR 64.

3 million in series D and debt round. The company plans to use the June 2025 funding to accelerate its artificial intelligence robotics' clinical development, partnerships, and global presence.